Skip to main content

Doxorubicin + Trabectedin Tied to Increased Survival in Metastatic Leiomyosarcoma

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 6, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared with doxorubicin alone, according to a study published online Sept. 4 in the New England Journal of Medicine.

Patricia Pautier, M.D., from the Institut Gustave-Roussy in Villejuif, France, and colleagues conducted a phase 3 trial involving 150 patients with metastatic or unresectable leiomyosarcoma who had not received chemotherapy. Patients were randomly assigned to doxorubicin (six cycles) or doxorubicin plus trabectedin (six cycles), with continued trabectedin as maintenance therapy in patients in the doxorubicin-trabectedin group without disease progression. After six cycles of therapy, surgery was allowed to resect residual disease in each group.

The researchers found that at a median follow-up of 55 months, 47 and 60 patients in the doxorubicin-trabectedin and doxorubicin groups, respectively, had died. Median overall survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group (33 versus 24 months; adjusted hazard ratio for death, 0.65). Progression-free survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group, in a finding consistent with earlier reports (12 versus six months; adjusted hazard ratio for progression or death, 0.37).

"The trial results support the use of doxorubicin plus trabectedin for the first-line treatment of advanced or metastatic leiomyosarcomas, offering hope for improved outcomes in this challenging disease area," the authors write.

The study was partially funded by PharmaMar, the manufacturer of trabectedin.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

Increases in Incidence Rates of Some Cancers Seen in Early-Onset Age Groups

THURSDAY, May 15, 2025 -- The incidence rates of 14 cancers have increased in early-onset age groups, with increases in older-onset age groups also occurring in most of these...

Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma

WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.